Short answer
Biohaven Ltd. (BHVN) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$137M
- +30.7% YoY · −5.2% QoQ
- EPS (diluted)
- −$0.92
- +52.6% YoY · −4.5% QoQ
Source: XBRL data from the Biohaven Ltd. (BHVN) Q2 2026 10-Q on SEC EDGAR. USD.
Biohaven Ltd. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $0, with no product sales revenue generated
- Commercial pipeline led by BHV-1300, BHV-1400, opakalim and taldefgrobep
- Near-term milestones: RISE 3 results, taldefgrobep Phase 2 results and BHV-1400 pivotal study targeted for second half of 2026
Risk Factors
- No risk-factors section provided in the submitted filing excerpt
- No newly added or materially updated risks identifiable from the excerpt
- No regulatory, legal, operational, competitive, market, or financial risks disclosed in the excerpt
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Biohaven Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.